SCHEMBL22874577

SCHEMBL22874577

CC(C)(C)Nc1ccc(OCc2cccc(F)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 13/20 0.60
▸ GRM5 P41594 1/20 0.55
▸ NR4A2 P43354 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ PLA2G1B P04054 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ ATG4B Q9Y4P1 1/20 0.54
▸ PARP10 Q53GL7 1/20 0.53
▸ MAOA P21397 1/20 0.50
▸ SCN9A Q15858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343925 0.84 MAOB (0.65) MAOBNR4A2KDM4EALDH1A1LMNA
SCHEMBL22874619 0.83 MAOB (0.64) MAOBNR4A2ALDH1A1GAAMAPT
SCHEMBL22874541 0.83 MAOB (0.62) MAOBKDM4EALDH1A1LMNA
SCHEMBL22967634 0.83 MAOB (0.60) MAOBMAOA
SCHEMBL22967750 0.82 MAOB (0.56) MAOBNR4A2ALDH1A1LMNAPARP10
SCHEMBL27619660 0.82 MAOB (0.67) MAOBNR4A2KDM4EALDH1A1LMNA
SCHEMBL12347496 0.82 AR (0.60) MAOBKDM4EALDH1A1LMNAGAA
SCHEMBL22874674 0.82 MAOB (0.71) MAOBNR4A2KDM4EALDH1A1LMNA
SCHEMBL22967760 0.81 MAOB (0.65) MAOBGRM5NR4A2PARP10MAOA
SCHEMBL12261786 0.81 MAOB (0.65) MAOBGRM5NR4A2PARP10MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 — — US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 — — US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 MAOB 975/4885GRM5 1472/4885NR4A2 2040/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 MAOB 975/4885GRM5 1472/4885NR4A2 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback